Subtopic Deep Dive

← Atherosclerosis and Cardiovascular Diseases

LOX-1 Receptor in Atherosclerosis
Research Guide

What is LOX-1 Receptor in Atherosclerosis?

LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1) is a scavenger receptor that binds oxidized LDL, mediating endothelial dysfunction, monocyte adhesion, and plaque formation in atherosclerosis.

LOX-1 upregulation promotes oxLDL uptake in endothelial cells, leading to inflammation and foam cell formation (Pirillo et al., 2013, 733 citations). This receptor links oxidative stress and innate immunity in early lesion development (Hansson et al., 2002, 1023 citations). Over 700 citations document its role in vascular pathologies across 10+ listed papers.

Curated Papers

Key Challenges

Why It Matters

LOX-1 drives endothelial activation by oxLDL, accelerating atherosclerosis in high-risk patients with diabetes or hypertension (Pirillo et al., 2013). Blocking LOX-1 reduces monocyte adhesion and plaque progression, offering therapeutic targets beyond statins (Szmitko et al., 2003). In oxidative stress models, LOX-1 inhibition prevents early lesion formation, impacting cardiovascular disease prevention (Marchio et al., 2019).

Key Research Challenges

LOX-1 Signaling Complexity

LOX-1 activates NF-κB and MAPK pathways, but crosstalk with Nox enzymes complicates inhibition (Pirillo et al., 2013). Lassègue and Griendling (2009) detail Nox1-5 contributions to ROS amplification via LOX-1. Selective antagonists remain elusive due to overlapping pathways (581 citations).

Polymorphism Effects Variability

LOX-1 polymorphisms alter oxLDL binding affinity, but population-specific impacts vary (Pirillo et al., 2013). Shi and Vanhoutte (2017) link endothelial dysfunction in diabetes to genetic variants. Clinical translation stalls without large cohort validation.

Antagonist Development Barriers

LOX-1 blockade reduces plaque in models, but systemic effects cause off-target inflammation (Marchio et al., 2019). Kong et al. (2022) highlight signaling redundancy in therapeutic targeting. No approved inhibitors exist despite 733+ citations on potential.

Essential Papers

Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines

Irene Maeve Rea, David S. Gibson, Victoria McGilligan et al. · 2018 · Frontiers in Immunology · 1.2K citations

Cytokine dysregulation is believed to play a key role in the remodeling of the immune system at older age, with evidence pointing to an inability to fine-control systemic inflammation, which seems ...

The role of shear stress in the pathogenesis of atherosclerosis

Kristopher S. Cunningham, Avrum I. Gotlieb · 2004 · Laboratory Investigation · 1.1K citations

Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis

Göran K. Hansson, Peter Libby, Uwe Schönbeck et al. · 2002 · Circulation Research · 1.0K citations

This review considers critically the evidence for the involvement of mediators of innate and acquired immunity in various stages of atherosclerosis. Rapidly mobilized arms of innate immunity, inclu...

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

Peng Kong, Ziyang Cui, Xiao-Fu Huang et al. · 2022 · Signal Transduction and Targeted Therapy · 966 citations

Pathophysiology of Atherosclerosis

Shifa Jebari‐Benslaiman, Unai Galicia-García, Asier Larrea‐Sebal et al. · 2022 · International Journal of Molecular Sciences · 796 citations

Atherosclerosis is the main risk factor for cardiovascular disease (CVD), which is the leading cause of mortality worldwide. Atherosclerosis is initiated by endothelium activation and, followed by ...

LOX-1, OxLDL, and Atherosclerosis

Angela Pirillo, Giuseppe Danilo Norata, Alberico L. Catapano · 2013 · Mediators of Inflammation · 733 citations

Oxidized low-density lipoprotein (OxLDL) contributes to the atherosclerotic plaque formation and progression by several mechanisms, including the induction of endothelial cell activation and dysfun...

New Markers of Inflammation and Endothelial Cell Activation

Paul E. Szmitko, Chao‐Hung Wang, Richard D. Weisel et al. · 2003 · Circulation · 727 citations

2][3][4][5][6] The vascular endothelium, located at the interface of blood and tissue, is able to sense changes in hemodynamic forces and bloodborne signals and react by synthesizing and releasing ...

Reading Guide

Foundational Papers

Start with Pirillo et al. (2013, 733 citations) for core LOX-1/oxLDL mechanisms; Hansson et al. (2002, 1023 citations) for immunity context; Lassègue and Griendling (2009, 581 citations) for ROS integration.

Recent Advances

Study Marchio et al. (2019, 604 citations) for oxidative stress targeting; Kong et al. (2022, 966 citations) for signaling interventions; Jebari-Benslaiman et al. (2022, 796 citations) for pathophysiology updates.

Core Methods

OxLDL exposure assays, siRNA knockdown, NADPH oxidase inhibitors (DPI, apocynin), NF-κB/MAPK Western blots, and shear stress flow chambers (Cunningham and Gotlieb, 2004).

How PapersFlow Helps You Research LOX-1 Receptor in Atherosclerosis

Discover & Search

Research Agent uses searchPapers('LOX-1 atherosclerosis oxLDL') to retrieve Pirillo et al. (2013, 733 citations), then citationGraph reveals Hansson et al. (2002) and Lassègue (2009) clusters; exaSearch uncovers polymorphism studies linking to Shi (2017).

Analyze & Verify

Analysis Agent runs readPaperContent on Pirillo et al. (2013) to extract LOX-1/oxLDL mechanisms, verifies claims with CoVe against 10 papers, and uses runPythonAnalysis for ROS pathway correlation stats from abstracts; GRADE scores evidence as A for endothelial dysfunction links.

Synthesize & Write

Synthesis Agent detects gaps in LOX-1 antagonist trials via contradiction flagging across Kong (2022) and Marchio (2019); Writing Agent applies latexEditText for pathway diagrams, latexSyncCitations for 20+ refs, and latexCompile for review manuscript.

Use Cases

"Analyze LOX-1 expression data from atherosclerosis studies"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on expression levels from Pirillo 2013 + Jebari-Benslaiman 2022) → statistical plots of oxLDL correlation.

"Draft LaTeX review on LOX-1 signaling in plaque formation"

Synthesis Agent → gap detection → Writing Agent → latexEditText (add NF-κB section) → latexSyncCitations (Hansson 2002, Pirillo 2013) → latexCompile → PDF with mermaid LOX-1 pathway diagram.

"Find code for LOX-1 simulation models"

Research Agent → paperExtractUrls (Marchio 2019) → paperFindGithubRepo → githubRepoInspect → ROS-LOX-1 ODE solver code for Python sandbox replication.

Automated Workflows

Deep Research workflow scans 50+ atherosclerosis papers via searchPapers, prioritizes LOX-1/oxLDL clusters with citationGraph, outputs structured report on signaling (Pirillo 2013 core). DeepScan applies 7-step CoVe to verify antagonist efficacy claims from Kong (2022). Theorizer generates hypotheses on LOX-1/Nox synergies from Lassègue (2009) + Marchio (2019).

Try Doxa for LOX-1 Receptor in Atherosclerosis Research

Frequently Asked Questions

What defines LOX-1's role in atherosclerosis?

LOX-1 binds oxLDL to induce endothelial dysfunction and monocyte recruitment (Pirillo et al., 2013).

What methods study LOX-1 signaling?

Researchers use oxLDL binding assays, NF-κB luciferase reporters, and Nox inhibitor models (Lassègue and Griendling, 2009; Marchio et al., 2019).

What are key papers on LOX-1?

Pirillo et al. (2013, 733 citations) reviews LOX-1/oxLDL mechanisms; Hansson et al. (2002, 1023 citations) links to innate immunity.

What open problems exist?

Developing LOX-1-specific antagonists without off-target effects; validating polymorphisms in diverse cohorts (Kong et al., 2022; Shi and Vanhoutte, 2017).